重组组织型纤溶酶原激活剂静脉溶栓治疗高龄急性脑梗死疗效分析

目的探讨研究重组组织型纤溶酶原激活剂静脉溶栓治疗高龄急性脑梗死疗效分析。方法收集2009年6月—2011年6月期间入住该院的60例高龄急性脑梗死患者,随机分为溶栓组和正常对照组,每组30例,溶栓组给予重组组织型纤溶酶原激活剂0.9mg/kg溶栓治疗,24h后经头颅CT检查无出血后口服肠溶阿司匹林100mg,1次/d。正常对照组自入院24h开始口服给予肠溶阿司匹林100mg,1次/d。结果两组患者与治疗前相比,随着时间的延长神经功能缺损评分(NIHSS)明显下降,有统计学差异(P<0.05),溶栓组与正常对照组相比,神经功能缺损评分(NIHSS)下降,差异有统计学意义(P<0.05),在治疗21d时,溶栓组的显效率明显高于对照组。结论重组组织型纤溶酶原激活剂可以有效的治疗高龄急性脑梗死,效果显著,值得在临床上推广。

Recombinant tissue-type plasminogen activator and intravenous thrombolytic therapy in elderly patients with acute cerebral infarction analysis

Objective To investigate the study of recombinant tissue-type plasminogen activator and intravenous thrombolytic therapy in elderly patients with acute cerebral infarction. Methods From June 2009 to June 2011, admitted to our hospital 60 cases of elderly patients with acute cerebral infarction, thrombolytic group were randomly divided into normal control group, n = 30, the thrombolytic group were treated with recombinant tissue fibrinolytic plasminogen activator the 0.9mg/kg thrombolytic therapy, 24 hours after the head CT without bleeding, oral aspirin 100mg daily. Normal control group from 24 hours of admission orally given aspirin 100 mg daily. Results The two groups of patients before treatment, with the extension of the time neurologic deficit score （NIHSS）decreased significantly, a significant difference （P 〈 0.05）, thrombolysis group compared with the control group, neurological deficit scores （NIHSS）decreased, and the difference was statistically significant （P 〈 0.05）, in the treatment of 21d thrombolysis group was significantly higher efficiency. Conclusion The recombinant tissue-type plasminogen activator treatment of elderly patients with acute cerebral infarction, the effect is significant, worth in clinical t~ractice.